Pazopanib在婦癌的檢視

The role of pazopanib in gynecologic cancer

Pazopanib（Votrient®）乃一種對多項酪氨酸激酶抑制劑，主要能抑制血管內皮生長因子接受器1、2、3，血小板衍生生長因子接受器α、β，幹細胞因子接受器c-kit，跨膜醣蛋白接受器酪氨酸激酶和基礎纖維母細胞生長因子，是一種抑制血管生成和腫瘤生長的藥物。2012年4月，美國食品藥物管理局（FDA）通過pazopanib可用來治療晚期軟組織肉瘤。近期文獻，pazopanib對婦科癌症亦有臨床上的裨益和穩定病情，值得日後深入研究。

Pazopanib (Votrient®), a multi-tyrosine kinase inhibitor, exerts antiangiogenic properties by inhibiting vascular endothelial factor receptors (VEGFR)-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)- α and β, stem-cell factor receptor (c-kit), transmembrane glycoprotein receptor tyrosine kinase(c-Fms) and fibroblast growth factor receptor (FGFR)- 1 and 3. It was approved by the Unit States Food and Drug Administration (FDA) as a treatment for advanced soft tissue sarcoma in the April of 2012. After reviewed the literature, there identified that the pazopanib can produce meaningful clinical benefit and stabilization of gynecologic cancer.